ACC.25 Scientific Sessions 2025
Oral PCSK9 inhibitor cuts LDL-C in half
At 12 weeks AZD0780, a once-daily 30 mg oral small molecule PCSK9 inhibitor, added to standard of care, reduced LDL-C by 50.7%. The phase 2b trial, presented in the Featured Clinical Research V session at the American College of Cardiology Scientific Sessions in Chicago, USA…
read more »
YELLOW III: Evolocumab shows no gender or diabetes status differences for plaque stabilisation
Two post hoc analyses of the YELLOW III study revealed no differences in plaque stabilisation for patients with stable coronary artery disease taking PCSK9 inhibitors according to gender and whether they had diabetes mellitus (DM) or not. The studies, abstract 933-19 looking at sex differences1…
read more »
Triple therapy with PCSK9 inhibitors reduces coronary artery calcification
Coronary artery disease (CAD) patients taking triple therapy – PCSK9 inhibitors, icosapent ethyl (IPE) and statins – showed reduced rates of coronary artery calcification in comparison to patients taking just statins or statins plus IPE. The retrospective study, abstract 1262-68,1 presented at the American College…
read more »
Meta-analysis reveals PCSK9 inhibitors reduce risk of stroke
A meta-analysis revealed that PCSK9 inhibitors significantly reduce the risk of all-cause stroke by 25% and ischaemic stroke by 24%. The study, abstract 1083-39,1 presented at the American College of Cardiology Scientific Sessions in Chicago, USA (29-31 March 2025), revealed no benefit for haemorrhagic stroke,…
read more »
Single dose of evolocumab reduces slow flow/no-reflow during PCI
A single dose of the PCSK9 inhibitor evolocumab prior to percutaneous coronary intervention (PCI) significantly reduced incidence of the phenomenon of slow flow/no-reflow during PCI. The Japanese study, abstract 962-21,1 was presented during the Moderated Poster session at the American College of Cardiology Scientific Sessions…
read more »
